McKesson (MCK) is a Stock That “Defies The President,” Says Jim Cramer

Company Overview - McKesson Corporation (NYSE:MCK) is one of the largest healthcare products and services providers in America [2] - The company's shares have gained 42% over the past year but have decreased by 5% since late November [2] Analyst Ratings - Deutsche Bank raised McKesson's share price target to $904 from $861 and maintained a Buy rating, noting that the company's plans to exit its surgical business could be dilutive but may also enhance share price performance [2] - TD Cowen also maintained a Buy rating with a price target of $1,000, expressing optimism about McKesson's growth potential and ability to meet long-term targets [2] Market Context - Jim Cramer commented on McKesson in relation to President Trump's views on the healthcare industry, suggesting that potential pricing reforms could negatively impact the company [2] - Despite these concerns, McKesson's stock continues to reach 52-week highs, indicating resilience against political pressures [2]